Hyperkalemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Hyperkalemia is one of the most common acute electrolyte abnormalities, and it usually triggers a heightened therapeutic response due to its potential for causing cardiac arrhythmias. In individuals with normal kidneys, hyperkalemia function occurs relatively infrequently, but it can be much more common in patients with certain predisposing conditions. The frequency of hyperkalemia may vary according to the case mix of the studied population. Indeed, studies examining patients with chronic kidney disease (CKD) have reported a significantly higher incidence of hyperkalemia. The principal predictors of higher serum potassium levels in cohort studies were the presence of diabetes mellitus, higher protein intake, lower serum bicarbonate, white race, and, most importantly, lower eGFR, and patients at highest risk are those in whom there is a clustering of several risk factors.

·       The prevalence of hyperkalemia in CKD patients is considerably higher than in the general population. A recent review reports hyperkalemia frequency as high as 40-50% in the CKD population compared to 2-3% in general.

 

Thelansis’s “Hyperkalemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hyperkalemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Hyperkalemia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Hyperkalemia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Hyperkalemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Hyperkalemia, Hyperkalemia market outlook, Hyperkalemia competitive landscape, Hyperkalemia market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)